Oxford Nanopore Technologies plc (ONT) — Investment Research Note

Executive summary

Oxford Nanopore develops and sells nanopore-based DNA/RNA sequencing devices, consumables, and workflows used in ~125 countries across Research, Clinical, BioPharma and Industrial end-markets. The operating trajectory has been steady but heavily loss-making, with revenue growing from £183m (FY24) to £223.9m (FY25, +24% CC) and adjusted EBITDA losses narrowing from £(117.9)m → £(86.7)m → £(22.1)m in H1 26, backed by 400bps gross-margin expansion to 62.2% and guidance to adjusted EBITDA breakeven in FY27 2026-08 interims. The single most important point for valuation today is whether the newly reaffirmed 2030 targets (>$700m revenue, >15% adj EBITDA margin) are credible — the current 179p share price already appears to bake in a reasonable path to those numbers after a ~55% rally in the last 30 days.

Fair value estimate

Methodology: blended DCF-style / forward EV-to-2030-EBITDA approach given the pre-profit status.

• 2030 targets: >$700m revenue at >15% adj EBITDA margin ⇒ $105–$130m adj EBITDA (£85–£105m at plausible FX).
• Applying 18–25x forward EBITDA (justifiable for a differentiated tools/platform business with 65%+ terminal GM) gives 2030 EV of £1.5–£2.6bn.
• Discounting back 4 years at 10% and adjusting for net cash (£235m today, but burning down to breakeven) gives a present fair-value equity range of £1.05bn – £1.65bn, or ~110p – ~170p per share.
• Mid-point fair value: ~140p (implied market cap ~£1.36bn).
• Downside vs current 179p: ~ -22% (overvalued by ~22%) after the recent rally.

Cross-check: EV/Sales of 4-5x forward FY27E (£340m) implies £1.4–£1.7bn — consistent.

Sector context

Sector classification (Health Care / Life Sciences Tools & Diagnostics) is confirmed. ONT's growth is above sector average (mid-20% CC vs peers in high-single-digits), but its profitability is materially below peers (still loss-making vs Illumina, Danaher, Thermo Fisher all deeply profitable). Balance sheet quality (net cash, no debt) is above average for this stage. Closest listed peers: Illumina (ILMN, direct short-read competitor), Pacific Biosciences (PACB, long-read peer), 10x Genomics (TXG). ONT trades at a growth premium to PACB (also loss-making) and a large P/S premium to profitable ILMN.

Investment thesis (three concrete reasons)

1. Operating leverage is now unlocking visibly. H1 26 revenue grew 12.3% CC while adjusted operating costs fell 6.9%, driving gross margin +400bps to 62.2% and halving the adjusted EBITDA loss to £(22.1)m — with consumables GM already at 75.4% 2026-08 interims. The FY26 guidance for adjusted opex growth of -2% to 0% (down from 0-5%) demonstrates continued cost discipline.
2. Differentiated technology with expanding applied-market footprint. Only platform capable of direct native DNA/RNA sequencing at any read length; won new $20m licensing deal + $15m committed product purchases from a global diagnostics company post-period; Clinical revenue +35.4% and BioPharma +25.0% in H1 26 2026-08 interims. First IVD product (GridION Dx) achieved CE/UKCA certification.
3. Fortress balance sheet with no dilution risk near-term. £234.5m cash/liquid investments at H1 26, no debt (only £41.8m leases), and cash burn narrowing toward breakeven 2026-08 interims. Directors' going-concern assessment confirms funded through breakeven under stress scenarios.

Key risks (three concrete reasons)

1. China and geopolitical exposure. APAC revenue -8.4% CC in H1 26 with China -15.7% reflecting export-control restrictions; recovery to growth targeted in 2027 but not guaranteed 2026-08 interims.
2. Competition intensifying and IP litigation ongoing. Roche's short-read platform launch (SBX) noted at FY24 results, plus active patent litigation against MGI/BGI in Australia and UK — outcome uncertain 2026-03 annual results. Illumina remains dominant incumbent.
3. Execution risk under new CEO / repeated H1 shortfalls. New CEO Francis Van Parys took over March 2026 and immediately restructured strategy; H1 26 revenue came in below management expectations per the July 2026 trading update; H1 25 also required restructuring charges. Track record of H1 misses 2026-07 trading update, 2025-09 interims.

Operating leverage

This is a genuinely high-operating-leverage business at inflection. The cost base is heavily fixed: 1,314 average FTEs at H1 26 with adjusted opex of £125m annualised and R&D (£75-90m) largely people-costs. Consumables carry ~75% gross margin, so incremental consumable revenue drops to profit at ~£0.75 per £1. Devices/Services margin has improved from ~23% (FY23) to 34% (H1 26). With FY26 adjusted opex flat-to-down and revenue growing 16-20% CC, a 10-20% revenue upside surprise would plausibly translate into a £25–£50m EBITDA swing — enough to close two-thirds of the adjusted EBITDA loss in a single year. The inflection to breakeven at FY27 confirms the sensitivity. Score: high 2026-08 interims, 2026-03 annual results.

Value-trap signals

None identified. Revenue is growing, balance sheet is clean, R&D pipeline is credible, no dividend to cut, no going-concern doubts, no related-party issues. The main concern is not a value trap but rather that recent price rally has closed most of the discount.

Earnings vs expectations

• FY23 (reported Mar-24): Broadly in line with guidance; £169.7m revenue in line; noted EGP contract restructuring at year-end. Met.
• FY24 (reported Mar-25): 11.1% CC growth, in line with guidance. Met.
• FY25 (reported Mar-26): 24.2% CC growth, slightly ahead of top end of guided 20-23% range. Beat.
• H1 26 (reported Aug-26): 12.3% CC growth, below management expectations per July trading update; FY26 organic guidance cut from 16-20% underlying (previously interpreted as top-end). Miss.

Pattern: broadly met annual guidance with FY25 beat, but H1 26 was a clear miss and H1 25 also required unplanned restructuring — the operating trajectory is improving but revenue delivery has been lumpy.

Conviction

Conviction: 3 (moderate).

Anchors: (i) clean disclosure with detailed adjusted EBITDA reconciliation and quarterly cadence; (ii) management has provided explicit 2027/2028/2030 targets against which progress is measurable; (iii) multiple valuation lenses converge on a similar £1.0–£1.7bn range.

Caveats: (i) fair value is highly sensitive to whether 2030 revenue and margin targets are met — a 25% miss on either compounds badly; (ii) still loss-making with no profits history to anchor conventional multiples.

Driver scoring rationale for overall_score

This is a partial fit for the investor profile. Positives: excellent operating leverage now inflecting, fortress balance sheet, differentiated platform. Negatives: AI-receiver angle is thin (uses AI internally in basecalling; not a direct picks-and-shovels play), valuation is no longer cheap after +55% one-month rally, and profitability is still prospective rather than proven. Overall score lands in the "partial fit" band around 400.